RESUMO
Introduction: An important gap within modern medicine is the lack of enough comparative effectiveness research of marketed medicines. Low-risk pragmatic randomized controlled trials (pRCTs) are those conducted resembling usual clinical practice that poses no or minimal incremental risk compared with normal clinical practice.Areas covered: This review addresses one important hurdle in the conduct of low-risk pRCTs: the need to seek participants' written informed consent.Expert opinion: The CIOMS ethical guidelines consider that any research that (a) would not be feasible or practicable to carry out without the waiver or modification, (b) has important social value, and (c) poses no more than minimal risks to participants, and that is approved by the relevant research ethics committee, could be conducted without participants' consent. It is clear that these provisions are applicable to some low-risk RCTs. Recently a research on the EU-CTR registry showed that only 2% of all ongoing phase 4 RCTs could have fulfilled the CIOMS provisions following the investigators' assessment. The EU clinical trial regulation - and that of other jurisdictions - should be debated on the suitableness of the conduct with an alteration or waiver of participants' consent of those low-risk pRCTs that fulfill the three CIOMS provisions.
Assuntos
Pesquisa Comparativa da Efetividade/métodos , Consentimento Livre e Esclarecido , Ensaios Clínicos Controlados Aleatórios como Assunto/métodos , Pesquisa Comparativa da Efetividade/ética , Pesquisa Comparativa da Efetividade/legislação & jurisprudência , Comitês de Ética em Pesquisa , Ética em Pesquisa , Guias como Assunto , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto/ética , Ensaios Clínicos Controlados Aleatórios como Assunto/legislação & jurisprudência , RiscoRESUMO
The SUPPORT trial highlights ethical challenges raised by comparative effectiveness randomized controlled trials (ceRCTs) involving one or more usual care interventions. Debate about the SUPPORT trial has focused on whether study interventions posed "reasonably foreseeable risks" to enrolled infants and, thereby, reflects a preoccupation with U.S. regulations. As ceRCTs are conducted globally, our analysis of the SUPPORT trial is grounded in internationally accepted ethical principles. We argue that the central ethical issue raised by the SUPPORT trial is the following: should the SUPPORT trial interventions be conceptualized as practice, or research? The answer to this question has important implications for "downstream" ethical requirements-including whether the usual care interventions in ceRCTs require research ethics committee review, undergo harm-benefit analysis, and are included in informed consent documents-and it is antecedent to the development of ethical guidance for ceRCTs.
Assuntos
Pesquisa Comparativa da Efetividade/ética , Oxigenoterapia/efeitos adversos , Oxigenoterapia/métodos , Ensaios Clínicos Pragmáticos como Assunto/ética , Humanos , Recém-Nascido , Recém-Nascido Prematuro , Consentimento Livre e Esclarecido , Oximetria , Oxigênio/sangue , Síndrome do Desconforto Respiratório do Recém-Nascido/mortalidade , Síndrome do Desconforto Respiratório do Recém-Nascido/terapia , Retinopatia da Prematuridade/etiologia , Retinopatia da Prematuridade/prevenção & controleRESUMO
OBJECTIVES: Pragmatic trials evaluate the comparative benefits, risks, and burdens of health care interventions in real-world conditions. Such studies are now recognized as valuable to the perimarketing stage of drug development and evaluation, with early pragmatic trials (EPTs) being explored as a means to generate real-world evidence at the time of regulatory market approval. In this article, we present an analysis of the ethical issues involved in informed consent for EPTs, in light of the generally recognized concern that traditional ethical rules governing randomized clinical trials, such as lengthy informed consent procedures, could threaten the "real world" nature of such trials. Specifically, we examine to what extent modifications (waivers or alterations) to regulatory consent for EPTs would be ethical. METHODS: We first identify broadly accepted necessary conditions for modifications of informed consent (namely, the research involves no more than minimal risk of harm, the research is impracticable with regulatory consent, and the alternative to regulatory consent does not violate legitimate patient expectations) and then apply those criteria to the premarket and early postmarket contexts. RESULTS AND CONCLUSIONS: The analysis shows that neither waivers nor alterations of regulatory consent for premarket EPTs will be ethically permissible. For postmarket EPTs with newly approved interventions, waivers of consent will be ethically problematic, but some studies might be conducted in an ethical manner with alterations to regulatory consent.
Assuntos
Pesquisa Comparativa da Efetividade/ética , Consentimento Livre e Esclarecido/ética , Ensaios Clínicos Controlados Aleatórios como Assunto/métodos , Aprovação de Drogas , Desenho de Fármacos , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto/éticaRESUMO
BACKGROUND: Ethical issues related to comparative effectiveness research, or research that compares existing standards of care, have recently received considerable attention. In this paper we focus on how Ethics Review Committees (ERCs) should evaluate the risks of comparative effectiveness research. MAIN TEXT: We discuss what has been a prominent focus in the debate about comparative effectiveness research, namely that it is justified when "nothing is known" about the comparative effectiveness of the available alternatives. We argue that this focus may be misleading. Rather, we should focus on the fact that some experts believe that the evidence points in favor of one intervention, whereas other experts believe that the evidence favors the alternative(s). We will then introduce a case that illustrates this point, and based on that, discuss how ERCs should deal with such cases of expert disagreement. CONCLUSION: We argue that ERCs have a duty to assess the range of expert opinions and based on that assessment arrive at a risk judgment about the study under consideration. We also argue that assessment of expert disagreement is important for the assignment of risk level to a clinical trial: what is the basis for expert opinions, how strong is the evidence appealed to by various experts, and how can clinical trial monitoring affect the possible increased risk of clinical trial participation.
Assuntos
Pesquisa Comparativa da Efetividade/ética , Dissidências e Disputas , Revisão Ética , Comissão de Ética , Obrigações Morais , Medição de Risco/métodos , Ensaios Clínicos como Assunto/ética , Ética em Pesquisa , Humanos , Julgamento , Risco , Padrão de CuidadoRESUMO
Electronic health records (EHRs) provide opportunities to enhance patient care, embed performance measures in clinical practice, and facilitate clinical research. Concerns have been raised about the increasing recruitment challenges in trials, burdensome and obtrusive data collection, and uncertain generalizability of the results. Leveraging electronic health records to counterbalance these trends is an area of intense interest. The initial applications of electronic health records, as the primary data source is envisioned for observational studies, embedded pragmatic or post-marketing registry-based randomized studies, or comparative effectiveness studies. Advancing this approach to randomized clinical trials, electronic health records may potentially be used to assess study feasibility, to facilitate patient recruitment, and streamline data collection at baseline and follow-up. Ensuring data security and privacy, overcoming the challenges associated with linking diverse systems and maintaining infrastructure for repeat use of high quality data, are some of the challenges associated with using electronic health records in clinical research. Collaboration between academia, industry, regulatory bodies, policy makers, patients, and electronic health record vendors is critical for the greater use of electronic health records in clinical research. This manuscript identifies the key steps required to advance the role of electronic health records in cardiovascular clinical research.
Assuntos
Doenças Cardiovasculares , Ensaios Clínicos como Assunto/métodos , Pesquisa Comparativa da Efetividade/métodos , Mineração de Dados , Registros Eletrônicos de Saúde , Projetos de Pesquisa , Acesso à Informação , Doenças Cardiovasculares/diagnóstico , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/terapia , Ensaios Clínicos como Assunto/ética , Pesquisa Comparativa da Efetividade/ética , Confidencialidade , Confiabilidade dos Dados , Mineração de Dados/ética , Registros Eletrônicos de Saúde/ética , Humanos , Registro Médico Coordenado , Integração de SistemasRESUMO
OBJECTIVE: Randomised controlled trials, a gold-standard approach to reduce uncertainties in clinical practice, are growing in cost and are often slow to recruit. We determined whether methodological approaches to facilitate large, efficient clinical trials were acceptable to UK research ethics committees (RECs). DESIGN: We developed a protocol in collaboration with parents, for a comparative-effectiveness, randomised controlled trial comparing two widely used blood transfusion practices in preterm infants. We incorporated four approaches to improve recruitment and efficiency: (i) point-of-care design using electronic patient records for patient identification, randomisation and data acquisition, (ii) short two-page information sheet; (iii) explicit mention of possible inclusion benefit; (iv) opt-out consent with enrolment as the default. With the support of the UK Health Research Authority, we submitted an identical protocol to 12 UK REC. SETTING: RECs in the UK. MAIN OUTCOME: Number of REC granting favourable opinions. RESULTS: The use of electronic patient records was acceptable to all RECs; one REC raised concerns about the short parent information sheet, 10 about inclusion benefit and 9 about opt-out consent. Following responses to queries, nine RECs granted a favourable final opinion and three rejected the application because they considered the opt-out consent process invalid. CONCLUSIONS: A majority of RECs in this study consider the use of electronic patient record data, short information sheets, opt-out consent and mention of possible inclusion benefit to be acceptable in neonatal comparative-effectiveness research. We identified a need for guidance for RECs in relation to opt-out consent processes. These methods provide opportunity to facilitate large randomised controlled trials.
Assuntos
Coleta de Amostras Sanguíneas/ética , Pesquisa Comparativa da Efetividade/ética , Transfusão de Eritrócitos/ética , Doenças do Recém-Nascido/terapia , Neonatologia/ética , Ensaios Clínicos Controlados Aleatórios como Assunto/ética , Transfusão de Eritrócitos/métodos , Humanos , Recém-Nascido , Medição de Risco , Fatores de Risco , Experimentação Humana Terapêutica/ética , Reino UnidoRESUMO
BACKGROUND: Comparative effectiveness research (CER) and pragmatic clinical trials commonly test interventions that are in routine use and pose minimal incremental risk or burdens to patients who participate in this research. The objective of this study was to elicit the range of patients' views and opinions regarding a variety of different types of research on usual medical practices, especially notification and authorization for them. METHODS: We conducted twelve focus groups with adults in five U.S. cities-six focus groups addressing CER ("CER groups") and six groups addressing research involving hospital operations and clinician interventions ("Operations groups"). Participants discussed hypothetical research studies and potential methods of notifying patients and obtaining their authorization to participate. Group discussions were recorded, transcribed, and coded to identify patients' views related to research on standard medical practice. RESULTS: A total of ninety six people participated. Twelve key themes emerged from participants' discussions of the hypothetical research studies; these themes were then grouped into four general categories: clinical care; notification and authorization; communication; and conduct and design of research. The desire to be actively notified and asked was more prominent with regard to CER studies than with regard to Operations studies. CONCLUSIONS: Our data suggest that effective policy and guidance will involve balancing different patients' interests and potentially different sets of interests for different types of research studies on usual medical practices.
Assuntos
Pesquisa Comparativa da Efetividade/ética , Pesquisa Comparativa da Efetividade/métodos , Consentimento Livre e Esclarecido/psicologia , Participação do Paciente , Sujeitos da Pesquisa/psicologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Grupos Focais , Humanos , Masculino , Pessoa de Meia-Idade , Seleção de Pacientes , Ensaios Clínicos Pragmáticos como Assunto/ética , Pesquisa Qualitativa , Estados Unidos , Gravação em Vídeo , Adulto JovemRESUMO
BACKGROUND: Pragmatic trials comparing standard-of-care interventions may improve the quality of care for future patients, but raise ethical questions about limitations on decisional autonomy. We sought to understand how patients and physicians view and respond to these questions in the contexts of pragmatic trials and of usual clinical care. METHODS: We conducted scenario-based, semi-structured interviews with 32 patients with end-stage renal disease (ESRD) receiving maintenance hemodialysis in outpatient dialysis units and with 24 nephrologists. Each participant was presented with two hypothetical scenarios in which a protocolized approach to hemodialysis treatment time was adopted for the entire dialysis unit as part of a clinical trial or a new clinical practice. RESULTS: A modified grounded theory analysis revealed three major themes: 1) the value of research, 2) the effect of protocolized care on patient and physician autonomy, and 3) information exchange between patients and physicians, including the mechanism of consent. Most patients and physicians were willing to relinquish decisional autonomy and were more willing to relinquish autonomy for research purposes than in clinical care. Patients' concerns towards clinical trials were tempered by their desires for certainty for a positive outcome and for physician validation. Patients tended to believe that being informed about research was more important than the actual mechanism of consent, and most were content with being able to opt out from participating. CONCLUSIONS: This qualitative study suggests the general acceptability of a pragmatic clinical trial comparing standard-of-care interventions that limits decisional autonomy for nephrologists and patients receiving hemodialysis. Future studies are needed to determine whether similar findings would emerge among other patients and providers considering other standard-of-care trials.
Assuntos
Protocolos Clínicos , Falência Renal Crônica/terapia , Participação do Paciente , Pacientes/psicologia , Médicos/psicologia , Ensaios Clínicos Controlados Aleatórios como Assunto/psicologia , Diálise Renal/psicologia , Adulto , Idoso , Atitude do Pessoal de Saúde , Pesquisa Comparativa da Efetividade/ética , Feminino , Humanos , Consentimento Livre e Esclarecido/ética , Consentimento Livre e Esclarecido/psicologia , Entrevistas como Assunto , Masculino , Pessoa de Meia-Idade , Pesquisa Qualitativa , Diálise Renal/normas , Padrão de CuidadoRESUMO
We examine ethical challenges encountered in the design of an effectiveness trial (CTN-0051; X:BOT), comparing sublingual buprenorphine-naloxone (BUP-NX), an established treatment for opioid dependence, to the newer extended-release injectable naltrexone (XR-NTX). Ethical issues surrounded: 1) known poor effectiveness of one possible, commonly used treatment as usual control condition-detoxification followed by counseling without medication; 2) the role of patients' preferences for treatments, given that treatments were clinically approved and available to the population; 3) differences between the optimal "usual treatment" clinical settings for different treatments making it challenging to design a fair comparison; 4) vested interest groups favoring different treatments exerting potential influence on the design process; 5) potentially vulnerable populations of substance users and prisoners; 6) potential therapeutic misconception in the implementation of safety procedures; and 7) high cost of a large trial limiting questions that could be addressed. We examine how the design features underlying these ethical issues are characteristic of effectiveness trials, which are often large trials that compare treatments with varying degrees of existing effectiveness data and familiarity to patients and clinicians, in community-based treatment settings, with minimal exclusion criteria that could involve vulnerable populations. Hence, investigators designing effectiveness trials may wish to remain alert to the possibility of similar ethical issues.
Assuntos
Combinação Buprenorfina e Naloxona/uso terapêutico , Pesquisa Comparativa da Efetividade/métodos , Naltrexona/uso terapêutico , Antagonistas de Entorpecentes/uso terapêutico , Transtornos Relacionados ao Uso de Opioides/tratamento farmacológico , Ensaios Clínicos Controlados Aleatórios como Assunto/métodos , Administração Sublingual , Pesquisa Comparativa da Efetividade/ética , Aconselhamento , Preparações de Ação Retardada , Ética em Pesquisa , Humanos , Consentimento Livre e Esclarecido , Injeções Intramusculares , Preferência do Paciente , Segurança do Paciente , Prisioneiros , Ensaios Clínicos Controlados Aleatórios como Assunto/ética , Populações VulneráveisRESUMO
BACKGROUND: We explored the views of key stakeholders to identify the ethical challenges of pragmatic trials investigating pharmaceutical drugs. A secondary aim was to capture stakeholders' attitudes towards the implementation of pragmatic trials in the drug development process. METHODS: We conducted semistructured, in-depth interviews among individuals from different key stakeholder groups (academia and independent research institutions, the pharmaceutical industry, regulators, Health Technology Assessment (HTA) agencies and patients' organizations) through telephone or face-to-face sessions. Interviews were structured around the question "what challenges were experienced or perceived during the design, conduct and/or review of pragmatic trials." Respondents were additionally asked about their views on implementation of pragmatic trials in the drug development process. Thematic analysis was used to identify the ethically relevant features across data sets. RESULTS: We interviewed 34 stakeholders in 25 individual sessions and four group sessions. The four perceived challenges of ethical relevance were: (1) less controlled conditions creating safety concerns, (2) comparison with usual care potentially compromising clinical equipoise, (3) tailored or waivers of informed consent affecting patient autonomy, and (4) minimal interference with "real-world" practice reducing the knowledge value of trial results. CONCLUSIONS: We identified stakeholder concerns regarding risk assessment, use of suboptimal usual care as a comparator, tailoring of informed consent procedures and ensuring the social value of pragmatic trials. These concerns increased when respondents were asked about pragmatic trials conducted before market authorization.
Assuntos
Atitude do Pessoal de Saúde , Drogas em Investigação/uso terapêutico , Conhecimentos, Atitudes e Prática em Saúde , Ensaios Clínicos Pragmáticos como Assunto/ética , Projetos de Pesquisa , Pesquisadores/psicologia , Participação dos Interessados , Pesquisa Comparativa da Efetividade/ética , Termos de Consentimento/ética , Drogas em Investigação/efeitos adversos , Feminino , Humanos , Consentimento Livre e Esclarecido/ética , Entrevistas como Assunto , Masculino , Segurança do Paciente , Papel do Médico , Ensaios Clínicos Pragmáticos como Assunto/métodos , Pesquisa Qualitativa , Fatores de Risco , Equipolência Terapêutica , Resultado do TratamentoRESUMO
BACKGROUND/AIMS: In the context of research on medical practices, which includes comparative effectiveness research and pragmatic clinical trials, empirical studies have begun to raise questions about the extent to which institutional review boards' interpretations and applications of research regulations align with patients' values. To better understand the similarities and differences between these stakeholder groups, we compare and contrast two surveys: one of institutional review board professionals and one of patients, which examine views on consent for research on medical practices. METHODS: We conducted online surveys of two target populations between July 2014 and March 2015. We surveyed 601 human subjects research professionals out of 1500 randomly selected from the Public Responsibility in Medicine and Research membership list (40.1% response rate), limiting analysis to 537 respondents who reported having had institutional review board experience. We also surveyed 120 adult patients out of 225 approached at subspecialty clinics in Spokane, Washington (53.3% response rate). Our survey questions probed attitudes about consent in the context of research on medical practices using medical record review and randomization. The patient survey included three embedded animated videos to explain these concepts. RESULTS: A majority of institutional review board professionals distinguished between consent preferences for medical record review and randomization, ranked clinicians as the least preferred person to obtain participant consent (54.6%), and viewed written or verbal permission as the minimum acceptable consent approach for research on medical practices using randomization (87.3%). In contrast, most patients had similar consent preferences for research on medical practices using randomization and medical record review, most preferred to have consent conversations with their doctors rather than with researchers for studies using randomization (72.6%) and medical record review (67.0%), and only a few preferred to see research involving randomization (16.8%) or medical record review (13.8%) not take place if obtaining written or verbal permission would make the research too difficult to conduct. Limitations of our post hoc analysis include differences in framing, structure, and language between the two surveys and possible response bias. CONCLUSION: Our findings highlight a need to identify appropriate ways to integrate patient preferences into prevailing regulatory interpretations as institutional review boards increasingly apply research regulations in the context of research on medical practices. Dialogue between institutional review boards and research participants will be an important part of this process and should inform future regulatory guidance.
Assuntos
Pesquisa Biomédica/ética , Pesquisa Comparativa da Efetividade/ética , Pesquisa Comparativa da Efetividade/métodos , Consentimento Livre e Esclarecido/ética , Consentimento Livre e Esclarecido/psicologia , Participação do Paciente/psicologia , Médicos/psicologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Comitês de Ética em Pesquisa , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Projetos de Pesquisa , Inquéritos e Questionários , Estados UnidosAssuntos
Pesquisa Comparativa da Efetividade/ética , Consentimento Livre e Esclarecido/ética , Educação de Pacientes como Assunto/ética , Ensaios Clínicos Controlados Aleatórios como Assunto/ética , Pesquisa Comparativa da Efetividade/legislação & jurisprudência , Pesquisa Comparativa da Efetividade/métodos , Pesquisa Comparativa da Efetividade/normas , Dissidências e Disputas/legislação & jurisprudência , Europa (Continente) , Humanos , Recém-Nascido , Recém-Nascido Prematuro , Consentimento Livre e Esclarecido/legislação & jurisprudência , Consentimento Livre e Esclarecido/normas , Oxigenoterapia/efeitos adversos , Oxigenoterapia/ética , Oxigenoterapia/métodos , Educação de Pacientes como Assunto/legislação & jurisprudência , Educação de Pacientes como Assunto/normas , Seleção de Pacientes/ética , Ensaios Clínicos Controlados Aleatórios como Assunto/legislação & jurisprudência , Ensaios Clínicos Controlados Aleatórios como Assunto/métodos , Ensaios Clínicos Controlados Aleatórios como Assunto/normas , Projetos de Pesquisa , Retinopatia da Prematuridade/prevenção & controle , Estados UnidosAssuntos
Pesquisa Biomédica/ética , Serviços Médicos de Emergência , Sepse/diagnóstico , Pesquisa Biomédica/legislação & jurisprudência , Pesquisa Comparativa da Efetividade/ética , Pesquisa Comparativa da Efetividade/legislação & jurisprudência , Diagnóstico Precoce , Intervenção Médica Precoce , Comitês de Ética em Pesquisa , Ética em Pesquisa , Humanos , Consentimento Livre e Esclarecido/ética , Consentimento Livre e Esclarecido/legislação & jurisprudência , Estudos Observacionais como Assunto/ética , Estudos Observacionais como Assunto/legislação & jurisprudência , Sepse/terapia , Terapias em Estudo/ética , Estados Unidos , United States Dept. of Health and Human Services , United States Food and Drug AdministrationRESUMO
The Affordable Care Act includes provisions for the conduct of large-scale, patient-centered comparative effectiveness research. Such efforts aim toward the laudable moral goal of having evidence to improve health care decision making. Nevertheless, these pragmatic clinical research efforts that typically pose minimal incremental risk and are enmeshed in routine care settings perhaps surprisingly encounter an array of ethics and regulatory challenges and opportunities for academic health centers. An emphasis on patient-centeredness forces an examination of the appropriateness of traditional methods used to protect the rights, interests, and welfare of participants. At the same time, meaningful collaboration with patients throughout the research process also necessitates ensuring that novel approaches to research (including recruitment and consent) entail necessary protections regarding such issues as privacy. As the scientific and logistical aspects of this research are being developed, substantial attention is being focused on the accompanying ethics and regulatory issues that have emerged, which should help to facilitate ethically appropriate research in a variety of contexts.
Assuntos
Pesquisa Comparativa da Efetividade/ética , Avaliação de Resultados da Assistência ao Paciente , Ensaios Clínicos Pragmáticos como Assunto/ética , Centros Médicos Acadêmicos/ética , Centros Médicos Acadêmicos/legislação & jurisprudência , Pesquisa Comparativa da Efetividade/legislação & jurisprudência , Confidencialidade/ética , Confidencialidade/legislação & jurisprudência , Comitês de Ética em Pesquisa/ética , Comitês de Ética em Pesquisa/legislação & jurisprudência , Humanos , Disseminação de Informação/ética , Disseminação de Informação/legislação & jurisprudência , Consentimento Livre e Esclarecido/ética , Consentimento Livre e Esclarecido/legislação & jurisprudência , Patient Protection and Affordable Care Act/legislação & jurisprudência , Assistência Centrada no Paciente , Ensaios Clínicos Pragmáticos como Assunto/legislação & jurisprudência , Estados UnidosRESUMO
PCORnet, the National Patient-Centered Clinical Research Network, seeks to establish a robust national health data network for patient-centered comparative effectiveness research. This article reports the results of a PCORnet survey designed to identify the ethics and regulatory challenges anticipated in network implementation. A 12-item online survey was developed by leadership of the PCORnet Ethics and Regulatory Task Force; responses were collected from the 29 PCORnet networks. The most pressing ethics issues identified related to informed consent, patient engagement, privacy and confidentiality, and data sharing. High priority regulatory issues included IRB coordination, privacy and confidentiality, informed consent, and data sharing. Over 150 IRBs and five different approaches to managing multisite IRB review were identified within PCORnet. Further empirical and scholarly work, as well as practical and policy guidance, is essential if important initiatives that rely on comparative effectiveness research are to move forward.